aibioAgenus securities class action dismissed, plaintiff appeals; SEC closes investigation
Tickers AGEN
The District of Massachusetts dismissed In re Agenus Inc. Securities Litigation on March 24, 2026. The lead plaintiff appealed to the First Circuit, where briefing began in June. Derivative suits remain stayed.
Key facts
- Company
- Agenus Inc. (NASDAQ: AGEN)
- News type
- Legal
- Primary source
- Agenus 10-Q for the quarter ended June 30, 2026 (SEC EDGAR)
Agenus Inc. (Nasdaq: AGEN) said in its 10-Q filed Aug 7, 2026 that the lead plaintiff in a putative securities class action has appealed to the U.S. Court of Appeals for the First Circuit after a federal judge dismissed the case. The SEC also told the company on May 4, 2026 that it had concluded its investigation and does not intend to recommend an enforcement action against Agenus.
The class action is In re Agenus Inc. Securities Litigation, No. 1:24-cv-12299, filed in September 2024 in the U.S. District Court for the District of Massachusetts against Agenus and certain of its executives and directors. The filings name Agenus and Garo Armen, its chairman and chief executive officer. Four related derivative suits name certain executives and directors.
The case
The lead plaintiff's amended complaint, filed Feb. 7, 2025, alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. It claimed Agenus made false and misleading statements and omissions about the efficacy and commercial prospects of its cancer drug candidates botensilimab (BOT) and balstilimab (BAL). The lead plaintiff sought to represent all persons who bought Agenus securities between Jan. 23, 2023 and July 17, 2024 and sought damages, interest and costs, including attorneys' fees.
Defendants
The amended complaint named Agenus, three of its current officers and one member of its advisory board. The 10-Q names only Armen, in describing the appeal, and does not name the other officers or the advisory board member. Agenus's 10-K for 2024 lists Christine M. Klaskin, vice president finance, as its principal financial officer; no filing says she is a defendant.
The 10-Q also does not list the derivative defendants. Agenus's 10-K for 2024 names three of the derivative suits as Royse v. Armen, et al. (1:24-cv-12823), Chen v. Armen, et al. (1:24-cv-13088) and Ferraioli v. Armen, et al. (1:24-cv-13083). Agenus's board when those suits were filed, according to the 10-K it signed on March 17, 2025, was Armen, Jennifer S. Buell, Brian Corvese, Tom Harrison, Susan Hirsch and Timothy R. Wright. Ulf Wiinberg left the board effective Nov. 5, 2024, according to an 8-K. Armen is the first-named defendant in each caption; no filing says which of the other directors are defendants.
Where it stands
On March 24, 2026, the court granted Agenus's motion to dismiss the class action in its entirety, ruling in favor of the company and the individual defendants, and denied the lead plaintiff leave to amend. The lead plaintiff appealed in a case captioned Olsen v. Agenus, Inc., et al., No. 26-01421. Briefing began in June 2026. The lead plaintiff contends the court erred as a matter of law in dismissing the claims against Agenus and Armen. The company intends to vigorously defend the dismissal order.
The derivative actions were filed between November 2024 and January 2025. On May 2, 2025 the court consolidated the four actions in Case No. 1:24-cv-12823 and stayed all deadlines pending developments in the class action. They allege that defendants made false or misleading statements about BOT and BAL and seek damages and corporate governance reforms.
Why it matters to shareholders
The SEC investigation began in September 2024, when Agenus received a subpoena from the Boston Regional Office seeking records on certain product candidates, correspondence with the FDA and public disclosure. The company produced records and says it cooperated throughout. The SEC's notice said it had concluded its investigation as to the company.
For the class action appeal and the consolidated derivative suits, Agenus says it is unable to estimate a range of loss, if any, from an adverse outcome. Its 10-K for 2024 said it had recorded no accrual for a contingent liability. The 10-Q says the company is not currently a party to any other material legal proceedings and that litigation can have a material adverse effect because of defense and settlement costs and diversion of management resources. It does not mention insurance.